Schizophrenia and Psychoses

Featured Article

Old Challenges and New Directions in Managing Tardive Dyskinesia

Old Challenges and New Directions in Managing Tardive Dyskinesia

"Since the current generation of psychiatrists has been raised on second-generation antipsychotics and has relatively little experience with first-generation antipsychotics, keeping tardive dyskinesia in mind is not, on the whole, part of their experience or training," said Christoph U. Correll, MD.

Latest

FDA to Review Lumateperone for Treatment of Schizophrenia

FDA to Review Lumateperone for Treatment of Schizophrenia

Lumateperone and follow-on compounds are also being evaluated for bipolar depression, behavioral disturbance associated with dementia, sleep disturbances associated with neuropsychiatric disorders, and other neuropsychiatric conditions including major depressive disorder and autism.

Polygenic Risk Scores May Predict Antipsychotic Efficacy in Schizophrenia

Polygenic Risk Scores May Predict Antipsychotic Efficacy in Schizophrenia

The use of a polygenic risk score for schizophrenia can effectively predict an antipsychotic treatment response after a first episode of psychosis.

Psychotic Experiences May Predict Future Suicidal Behaviors

Psychotic Experiences May Predict Future Suicidal Behaviors

Psychotic experiences may be a clinical marker of risk for future suicidal behaviors.

Link Between Sleep Disturbances and Inflammatory Markers in Schizophrenia

Link Between Sleep Disturbances and Inflammatory Markers in Schizophrenia

Investigators examined the relationship between sleep disturbances and levels of anti-inflammatory markers in patients with schizophrenia.

Link Between Low Insight, Metacognitive Impairment in Schizophrenia

Link Between Low Insight, Metacognitive Impairment in Schizophrenia

Awareness of self and others may provide insight into one's own psychiatric challenges.

Motion-Processing Deficits Linked to Impaired Cognitive Function in Schizophrenia

Motion-Processing Deficits Linked to Impaired Cognitive Function in Schizophrenia

New study data show a correlation between motion processing deficiency and cognitive impairment in patients with schizophrenia.

Perseris Now Available for the Treatment of Schizophrenia in Adults

Perseris Now Available for the Treatment of Schizophrenia in Adults

Perseris, an atypical antipsychotic, has an extended-release delivery system that releases sustained levels of risperidone over 1 month.

The Challenges of Identifying Biomarkers of Psychiatric Illness

The Challenges of Identifying Biomarkers of Psychiatric Illness

There is minimal overlap in neurologic variations among individuals with severe psychiatric conditions such as schizophrenia spectrum disorders and bipolar disorder.

Cardioprotective Treatment May Reduce Adverse Effects in Schizophrenia

Cardioprotective Treatment May Reduce Adverse Effects in Schizophrenia

Investigators sought to determine whether cardioprotective medication after a myocardial infarction could reduce mortality rates in patients with schizophrenia.

Clozapine Monotherapy May Be Effective in Reducing the Severity of Antipsychotic-Induced Tardive Dyskinesia

Clozapine Monotherapy May Be Effective in Reducing the Severity of Antipsychotic-Induced Tardive Dyskinesia

These results provide support for switching antipsychotics to clozapine in patients with moderate to severe tardive dyskinesia.

Sign Up for Free e-newsletters